Eupraxia Pharmaceuticals Inc. reported $0 of revenue over the trailing twelve months. 6 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $0 (to FY2025). Net income: −$39M, trailing twelve months to FY2025. Free cash flow: −$29M, trailing twelve months to FY2025. EPS: −$1.03, trailing twelve months to FY2025.

EPRXEupraxia Pharmaceuticals Inc.

Healthcare

$7.58+26% 1Y

$7.58

$5.3352 weeks$9.12

EPRX as reported

Eupraxia Pharmaceuticals Inc. reported $0 of revenue over the trailing twelve months. 6 reported series are charted on this page, each one as filed.

Revenue, trailing twelve months · to FY2025 · every figure below is as filed, with no scoring applied

Net income: −$39M
Net income · +51% year on year · trailing twelve months to FY2025
Free cash flow: −$29M
Free cash flow · −3.2% year on year · trailing twelve months to FY2025
EPS: −$1.03
EPS · +36% year on year · trailing twelve months to FY2025

Details›

Every series Ryufin has for EPRX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$0	n/a	FY2025
Net income	−$39M	+51%	FY2025
EPS	−$1.03	+36%	FY2025
ROE	−47%	n/a	FY2025
ROA	−45%	n/a	FY2025
Free cash flow	−$29M	−3.2%	FY2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.